| To study the curative effect of Yiqi Yangyin Huoxue Fang on pulmonary fibrosis and its influence on inflammatory factors and pulmonary function. Methods:A total of 94 patients with pulmonary fibrosis treated in our hospital from December 2014 to December 2016 were randomly divided into the observation group (47 cases) and the control group (47 cases). The control group was treated with western medicine, and the observation group was treated with Yiqi Yangyin Huoxue Fang on the basis of the control group. The two groups were treated for 3 months. Results:The total effective rate of the observation group (8936%) was higher than that of the control group (7021%) (P<005); Cough, breathing difficulties and the two groups after treatment were lower rales (observation group: t=225430, 240091, 219675, the control group: t=140037, 149906, 151712, P<005); respiratory difficulties, cough, rales in the observation group after treatment were lower than control group (t=202334, 108108, 129694, P<005); IL-6, TGF-β1 and TNF-α decreased in two groups after treatment (observation group: t=254017, 166851, 243335, the control group: t=107510, 97017, 121940, P<005); the observation group after treatment IL-6, TGF-β1 and TNF-α lower than that of the control group (t=148318, 132045, 132847, P<005). The two groups after treatment FVC, FEV1 and DLco increased (observation group: t=124157, 142608, 115487, the control group: t=75293, 85027, 59400, P<005) and the observation group after treatment FVC, FEV1 and DLco was higher than the control group (t=61000, 59271, 52539, P<005). There were no obvious adverse reactions in the two groups. Conclusion:Yiqi Yangyin Huoxue Fang has significant curative effect on pulmonary fibrosis, can reduce the levels of inflammatory factors IL-6, TGF-β1 and TNF-α, and improve the lung function of patients, which has important research significance.